Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 3;15(7):878.
doi: 10.3390/genes15070878.

The Evolution of Genetic Variability at the LRRK2 Locus

Dylan T Guenther  1 , Jordan Follett  1 , Rim Amouri  2 , Samia Ben Sassi  2 , Faycel Hentati  2 , Matthew J Farrer  1
Affiliations

The Evolution of Genetic Variability at the LRRK2 Locus

Dylan T Guenther et al. Genes (Basel). .

Abstract

Leucine-rich repeat kinase 2 (LRRK2) c.6055G>A (p.G2019S) is a frequent cause of Parkinson's disease (PD), accounting for >30% of Tunisian Arab-Berber patients. LRRK2 is widely expressed in the immune system and its kinase activity confers a survival advantage against infection in animal models. Here, we assess haplotype variability in cis and in trans of the LRRK2 c.6055G>A mutation, define the age of the pathogenic allele, explore its relationship to the age of disease onset (AOO), and provide evidence for its positive selection.

Keywords: LRRK2; Parkinson’s disease; evolution.

PubMed Disclaimer

Conflict of interest statement

M.J.F. reports US patents associated with LRRK2 mutations and mouse models (8409809, 8455243) and methods of treating neurodegenerative disease (20110092565).

Figures

Figure 1
Figure 1
Three clades defined by the variability in 5 SNPs (rs2638245, rs10878199, rs2638271, rs2708438, and rs1388587) were identified within this sample. (a) An unrooted maximum likelihood phylogenic tree shows three prominent clades in this Tunisian cohort. These three clades are defined by: TTCA[G/C], n = 41, freq = 0.24; CTG[A/G]G, n = 73, freq = 0.43; and TT[C/G]GC, n = 54, freq = 0.32, respectively. (b) The age of initial symptom onset for affected heterozygotes in each of the three trans clades. No significant difference was observed (z = 0.40, p = 0.69).
Figure 2
Figure 2
Absolute value of elevated iHSs > 2.5 across chromosome 12. A cluster of elevated iHSs can be observed within the 39.8–41.0 Mb range, which encompasses LRRK2 p.G2019S haplotypes and is consistent with positive selection within the region. LRRK2 p.G2019S is encoded by GRCh38 NC_000012.12:g.40340400G>A (‘A’ is the mutant allele, as boxed above).
See this image and copyright information in PMC

References

    1. Mata I.F., Hutter C.M., González-Fernández M.C., de Pancorbo M.M., Lezcano E., Huerta C., Blazquez M., Ribacoba R., Guisasola L.M., Salvador C., et al. Lrrk2 R1441G-Related Parkinson’s Disease: Evidence of a Common Founding Event in the Seventh Century in Northern Spain. Neurogenetics. 2009;10:347–353. doi: 10.1007/s10048-009-0187-z. - DOI - PMC - PubMed
    1. Nuytemans K., Rademakers R., Theuns J., Pals P., Engelborghs S., Pickut B., de Pooter T., Peeters K., Mattheijssens M., Van den Broeck M., et al. Founder Mutation p.R1441C in the Leucine-Rich Repeat Kinase 2 Gene in Belgian Parkinson’s Disease Patients. Eur. J. Hum. Genet. 2008;16:471–479. doi: 10.1038/sj.ejhg.5201986. - DOI - PubMed
    1. Criscuolo C., De Rosa A., Guacci A., Simons E.J., Breedveld G.J., Peluso S., Volpe G., Filla A., Oostra B.A., Bonifati V., et al. The LRRK2 R1441C Mutation Is More Frequent than G2019S in Parkinson’s Disease Patients from Southern Italy. Mov. Disord. 2011;26:1733–1736. doi: 10.1002/mds.23735. - DOI - PubMed
    1. Farrer M.J., Stone J.T., Lin C.-H., Dächsel J.C., Hulihan M.M., Haugarvoll K., Ross O.A., Wu R.-M. Lrrk2 G2385R Is an Ancestral Risk Factor for Parkinson’s Disease in Asia. Park. Relat. Disord. 2007;13:89–92. doi: 10.1016/j.parkreldis.2006.12.001. - DOI - PubMed
    1. Shu L., Zhang Y., Sun Q., Pan H., Tang B. A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson’s Disease. Front. Aging Neurosci. 2019;11:13. doi: 10.3389/fnagi.2019.00013. - DOI - PMC - PubMed

Substances

LinkOut - more resources